BioCentury
ARTICLE | Company News

BMS, Pharmacyclics to test Opdivo/Imbruvica combo

October 14, 2014 2:08 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) partnered with Pharmacyclics Inc. (NASDAQ:PCYC) and Johnson & Johnson (NYSE:JNJ) to evaluate BMS's Opdivo nivolumab in combination with Imbruvica ibrutinib in a Phase I/II trial to treat non-Hodgkin's lymphoma. Pharmacyclics spokesperson Samina Bari and BMS spokesperson Ken Dominski both declined to disclose financial terms or the trial's start date.

Earlier this month, BMS partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to test combinations of Opdivo with three Novartis compounds to treat non-small cell lung cancer (NSCLC) (see BioCentury Extra, Oct. 6). ...